NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free MAIA Stock Alerts $2.89 -0.15 (-4.93%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$2.85▼$3.1050-Day Range N/A52-Week Range$0.82▼$3.59Volume569,672 shsAverage Volume390,629 shsMarket Capitalization$59.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get MAIA Biotechnology alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA)MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.Read More MAIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAIA Stock News HeadlinesApril 27, 2024 | insidertrades.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie Acquires 19,665 SharesApril 30, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 29, 2024 | marketwatch.comMAIA Biotechnology Shares Hit 52-Week High After Director Stock PurchaseApril 29, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private PlacementApril 28, 2024 | finance.yahoo.comMAIA Biotechnology, Inc. (MAIA)April 23, 2024 | businesswire.comMAIA Biotechnology Announces $1.00 Million Private PlacementApril 5, 2024 | businesswire.comMAIA Biotechnology to Present at Two Investor Conferences in April 2024May 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 4, 2024 | msn.comeFFECTOR shelves tomivosertib in NSCLC following Phase II failureMarch 28, 2024 | investing.comMAIA Biotechnology directors buy shares amid development pushMarch 28, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro GuerreroMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces $1.33 Million Private PlacementMarch 22, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private PlacementMarch 21, 2024 | businesswire.comMAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory BoardMarch 16, 2024 | finance.yahoo.comDirector Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)March 14, 2024 | msn.comMAIA Biotechnology rises 3% on $2.92M private placementMarch 7, 2024 | finance.yahoo.comMAIA Biotechnology to Participate in the 36th Annual ROTH ConferenceMarch 7, 2024 | investing.comMAIA Biotechnology nears end of Phase 2 cancer trialMarch 6, 2024 | markets.businessinsider.comMAIA Announces Positive Data From Phase 2 THIO Clinical Trial For NSCLC; Stock Rises 8%March 6, 2024 | finance.yahoo.comMAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer PatientsMarch 5, 2024 | finance.yahoo.comMAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to ShareholdersFebruary 27, 2024 | globenewswire.comMAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific AdvisorFebruary 23, 2024 | msn.comMAIA Biotechnology concludes subject enrolment in NSCLC therapy trialSee More Headlines Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:MAIA CUSIPN/A CIKN/A Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-520.95% Return on Assets-233.25% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book96.33Miscellaneous Outstanding Shares20,580,000Free Float12,970,000Market Cap$59.48 million OptionableNot Optionable Beta0.04 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Vlad Vitoc M.B.A. (Age 53)M.D., Co-Founder, President, CEO & Chairman of the Board of Directors Comp: $715.55kDr. Sergei M. Gryaznov Ph.D. (Age 64)Chief Scientific Officer Comp: $524.77kMr. Jeffrey C. HimmelreichHead of FinanceLinda MoreiraCompany SecretaryKey CompetitorsJourney MedicalNASDAQ:DERMLantern PharmaNASDAQ:LTRNAssembly BiosciencesNASDAQ:ASMBLandos BiopharmaNASDAQ:LABPSCYNEXISNASDAQ:SCYXView All CompetitorsInsidersNgar Yee LouieBought 19,665 shares on 4/25/2024Total: $39,919.95 ($2.03/share)Stan SmithBought 170,940 shares on 3/14/2024Total: $199,999.80 ($1.17/share)Ramiro GuerreroBought 1,200 shares on 5/18/2023Total: $2,964.00 ($2.47/share)Cristian LuputBought 3,000 shares on 5/15/2023Total: $7,890.00 ($2.63/share)View All Insider Transactions MAIA Stock Analysis - Frequently Asked Questions Are investors shorting MAIA Biotechnology? MAIA Biotechnology saw a increase in short interest in March. As of March 31st, there was short interest totaling 845,100 shares, an increase of 66.2% from the March 15th total of 508,500 shares. Based on an average trading volume of 434,100 shares, the days-to-cover ratio is presently 1.9 days. Approximately 6.0% of the shares of the company are sold short. View MAIA Biotechnology's Short Interest. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.06. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MAIA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaUrgent Nvidia WarningAltimetryThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
